Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy

Abstract

Immunotherapy (IO), involving the use of immune checkpoint inhibition, achieves improved response-rates and significant disease-free survival for some cancer patients. Despite these beneficial effects, there is poor predictability of response and substantial rates of innate or acquired resistance, resulting in heterogeneous responses among patients. In addition, patients can develop life-threatening adverse events, and while these generally occur in patients that also show a tumor response, these outcomes are not always congruent. Therefore, predicting a response to IO is of paramount importance. Traditionally, tumor tissue analysis has been used for this purpose. However, minimally invasive liquid biopsies that monitor changes in blood or other bodily fluid markers are emerging as a promising cost-effective alternative. Traditional biomarkers have limitations mainly due to difficulty in repeatedly obtaining tumor tissue confounded also by the spatial and temporal heterogeneity of tumours. Liquid biopsy has the potential to circumvent tumor heterogeneity and to help identifying patients who may respond to IO, to monitor the treatment dynamically, as well as to unravel the mechanisms of relapse. We present here a review of the current status of molecular markers for the prediction and monitoring of IO response, focusing on the detection of these markers in liquid biopsies. With the emerging improvements in the field of liquid biopsy, this approach has the capacity to identify IO-eligible patients and provide clinically relevant information to assist with their ongoing disease management.

Clinical Applications of Liquid Biopsy in Colorectal Cancer Screening: Current Challenges and Future Perspectives

“…However, further scientific evidence is needed to clarify the similarities between PD-L1 detection on CTCs and tissue expression of PD-L1. Moreover, considering their rarity in the bloodstream, the utility of CTCs in immunotherapy is still in the early stages [ 156 ]. Nonetheless, emerging studies are documenting the role of extravesicles (EVs) as potential biomarkers for immunotherapy.…”

Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers – current evidence and future directions

“…The monitoring of ctDNA during ICI therapy has been investigated in stage IV MSI-H CRC in a number of small cases reports. In these studies, the following endpoints were analyzed: the quantitation of VAF, measurement of TMB and tracking of tumor-specific mutations such as TP53 , RAS and BRAF ( 113 ). Some studies have suggested that MSI-H CRC are often poorly-differentiated and produce significantly lower levels of serum tumor markers such as CEA and CA 19.9 ( 114 – 116 ) than well-differentiated tumors.…”

LiqBioer: a manually curated database of cancer biomarkers in body fluid

“…Gold standard molecular profiling is performed for resected or biopsied tumors ( 6 ). However, tumor biopsy is invasive, inconvenient and difficult to track in terms of temporal and spatial heterogeneity ( 7 ).…”